Product Description
Eliglustat is a potent and specific inhibitor of glucosylceramide synthase. Eliglustat is a new promising substrate reduction therapy (SRT) for Gaucher disease (GD). Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Eliglustat is a potent and specific inhibitor of glucosylceramide synthase. Eliglustat is a new promising substrate reduction therapy (SRT) for Gaucher disease (GD). Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Biovision | B1217 | Eliglustat DataSheet
Alternate Name/Synonyms: N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide hemi((2R,3R)-2,3-dihydroxysuccinate); Genz99067
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 491833-29-5
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₃H₃₆N₂O
Molecular Weight: 404.54
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO(>5 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent and specific glucosylceramide synthase inhibitor
MDL Number: N/A
PubChem CID: 23652731
SMILES: CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O
InChi: InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
InChi Key: FJZZPCZKBUKGGU-AUSIDOKSSA-N